Bultavo-3 bluetongue vaccine likely to require annual administration

The Bultavo-3 vaccine for sheep and cattle may require annual administration to maintain immunity against bluetongue virus serotype 3, according to Dr. Ruth Sanders of the Department of Agriculture. Manufacturer Boehringer Ingelheim has submitted data to competent authorities seeking a full year duration for the vaccine, Sanders stated during the Teagasc National Sheep Conference.

How is the Bultavo-3 vaccine administered?

Sheep require a single dose of the vaccine to build immunity over a three-week period. Cattle require a different protocol, starting with an initial shot followed by a booster dose three weeks later.

Dr. Sanders noted that cattle who complete this full primary course will likely only need an annual booster vaccine. The primary goal of the immunization is to reduce viraemia and prevent mortality and clinical signs caused by the virus.

Did You Know? While sheep achieve immunity after one shot and three weeks, cattle must receive an initial dose and a booster three weeks later to complete their primary course.

What is the current regulatory status of bluetongue vaccines?

The Health Products Regulatory Authority (HPRA) and the UK’s Veterinary Medicines Directorate currently list the duration of immunity for Bultavo-3 as “not established.”

This regulatory status is not unique to Bultavo-3. According to the source, the same “not established” designation applies to two other approved vaccines used in the UK and Ireland: Bluevac-3 and Syvazul BTV 3.

Expert Insight: Samantha Carter suggests that the gap between manufacturer data and regulatory labels highlights the cautious approach agencies take before officially confirming long-term immunity durations. This places the emphasis on clinical guidance and manufacturer submissions to bridge the information gap for farmers.

Why are veterinary inspectors recommending vaccination?

Dr. Sanders advised over 200 farmers at the conference to consider vaccinating their animals to mitigate risk. She described vaccination as “the best tool we have” to reduce clinical signs and viraemia.

Teagasc Sheep Conference 26th January

The recommendation follows reports of high mortality rates in continental EU countries. While cases in Ireland, England, and Wales have not shown the same clinical symptoms, Sanders highlighted that significant fertility issues are being reported in England.

What may happen with the virus by 2026?

The future prevalence and severity of the bluetongue virus remain uncertain. Dr. Sanders stated it is impossible to determine what the disease landscape will look like in 2026.

Because of this uncertainty, annual vaccination schedules could become the standard for maintaining livestock immunity. If the data submitted by Boehringer Ingelheim is accepted, the vaccine is likely to be administered on a yearly basis.

Frequently Asked Questions

What animals is Bultavo-3 designed for?
The vaccine provides active immunisation for sheep and cattle to prevent clinical signs and mortality caused by bluetongue virus serotype 3.

Which regulatory bodies oversee the vaccine in the UK and Ireland?
The Health Products Regulatory Authority (HPRA) and the UK’s Veterinary Medicines Directorate are the agencies listing the product characteristics.

What symptoms have been reported in England?
According to Dr. Ruth Sanders, significant fertility issues have been reported in England, though these differ from the high mortality levels seen in continental EU countries.

How do you view the balance between annual vaccine administration and the risk of livestock disease?